Genzyme Expands - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Genzyme Expands

ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Cambridge, MA (June 7)—Genzyme Corp. is growing, with a new biomanufacturing plant planned and other expansions nearing completion.

The company is investing EUR105 million (nearly $140 million) in a new 140,000-ft2 biomanufacturing plant in Lyon, France to replace its smaller plant in nearby Marcy l’Etoile. The new plant, which will be used to manufacture Genzyme’s transplantation treatment “Thymoglobulin,” will have more than twice the manufacturing capacity of the Marcy facility and will create as many as 50 new jobs. The facility’s nine-acre site leaves room for expansion should demand for Thymoglobulin continue to rise.

Genzye also is completing development of a new plant in Belgium, which will be used to produce monoclonal antibodies and proteins. The company intends to expand other facilities, including its Allston Landing protein manufacturing plant in Boston.  In addition, a new filling and packaging facility at Genzyme’s manufacturing site in Ireland recently received regulatory approvals.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here